HUMA
What one share of Humacyte holds
Biological Products, (No Diagnostic Substances)
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product.
Humacyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.50 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.50 |
| Cash and investments | $0.29 |
| Debt | $0.24 |
| Book value | $0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$11.54 | $0.06 | −$9.69 | — | −$60.17 |
| 2021 | — | −$0.66 | $0.01 | −$2.04 | — | — |
| 2022 | — | −$0.12 | $0.01 | −$0.70 | — | $1.13 |
| 2023 | — | −$1.07 | $0.02 | −$0.73 | — | $0.13 |
| 2024 | $0.00 | −$1.26 | $0.01 | −$0.84 | — | −$0.41 |
| 2025 | $0.01 | −$0.26 | $0.01 | −$0.67 | — | $0.02 |